Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply BioSpaceThe investment will expand Resilience's U.S.Metabolic & GLP-1Read full story pharminent July 31, 2026 (Last updated: August 3, 2026) BioSpace The investment will expand Resilience’s U.S. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo setback casts doubt on a new way to treat heart diseaseNext: Novo Nordisk’s Ziltivekimab Misses Primary Endpoint in Pivotal Cardiovascular Trial Related Stories Manufacturing GSK Cambridge Move Signals Shift in Drug Scale-Up Strategy pharminent July 29, 2026 Manufacturing GSK to quit Stevenage for new R&D site in Cambridge pharminent July 28, 2026 Manufacturing Trump Threatens 100%–200% Tariffs on Imported Generic Drugs pharminent July 22, 2026
